Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.46 |
| ▸ | MTOR | P42345 | 16/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008440 | 0.89 | PIK3CA (0.53) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL4013133 | 0.86 | PIK3CA (0.56) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL4004756 | 0.86 | ATR (0.60) | PIK3CAMTORPIK3CDATR | |
| SCHEMBL4011124 | 0.83 | ATR (0.52) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL4215038 | 0.82 | PIK3CA (0.54) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL4005634 | 0.82 | PIK3CA (0.57) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL27815347 | 0.81 | PIK3CA (0.46) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL3929781 | 0.80 | MTOR (0.56) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL3926275 | 0.78 | ATR (0.57) | PIK3CAMTORPIK3CDATRPIK3CG | |
| SCHEMBL4007053 | 0.78 | PIK3CA (0.53) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |